BACKGROUND Anemia is a common condition among surgical and critically ill patients and it is usually treated with allogenic blood transfusion (ABT). As ABT is associated with increased morbidity and mortality, alternative therapies for anemia in these patients are actively investigated. OBJECTIVES To asses the potential usefulness of intravenous iron therapy in critically-ill or surgical pati...

BACKGROUND Intravenous iron affects serum levels of intact fibroblast growth factor-23 (iFGF23) and its cleavage product c-terminal FGF23 (cFGF23) in iron-deficient people with normal renal function. We hypothesized that intravenous iron modulates iFGF23 and cFGF23 in haemodialysis patients differently according to the type of iron used. METHODS Prevalent, stable haemodialysis patients requir...

BACKGROUND AND OBJECTIVES This trial explores whether intravenous iron isomaltoside 1000 (Monofer®) results in a better regeneration of haemoglobin levels and prevents anaemia compared to placebo in preoperative non-anaemic patients undergoing cardiac surgery. STUDY DESIGN AND METHODS The trial is a prospective, double-blind, comparative, placebo-controlled trial of 60 non-anaemic patients un...

Background. Iron deficiency is the prevalent complication of inflammatory bowel disease (IBD). Herein, we investigated the effect of intravenous iron treatment on quality of life (QoL) in nonanemic and iron deficient IBD patients. Methods. Eighty-five IBD patients were recruited for this study. The patients were intravenously administered 500 mg iron sucrose in the first week of the study. Hema...

Objective – The aim of the study was to determine the efficacy and safety of intravenous iron preparations in a group of children with iron deficiency anemia who did not respond to oral iron supplementation. Materials and methods – We conducted a retrospective study on children who received intravenous iron sucrose and iron gluconate at University Children’s Hospital Rijeka between January 1, 2...

Hyperphosphatemia and anemia are common complications in patients with advanced CKD, and both contribute to their increasedmorbidity andmortality fromcardiovasculardisease. Fortunately, both conditions can be effectively treated with currently available therapeutic agents: phosphate binders, erythropoiesis-stimulating agents (ESAs), and iron supplementation. Regrettably, we now recognize that u...

In the review paper an issue of the administration of iron containing drugs in the treatment of anemia in non-dialyzed patients with chronic kidney disease (CKD) is presented. Iron deficiency in patients with CKD (serum ferritin concentration below 100 ng/ml, transferrin saturation below 20%) occurs in 20-70% of cases. Prevalence of iron deficiency depends on stage of CKD and patients' gender. ...

Background: In patients treated by maintenance hemodialysis the relationship to survival of hemoglobin level and administered epoetin-! and intravenous iron is controversial. The study aim was to determine effects on patient survival of administered epoetin-! and intravenous iron, and of hemoglobin and variables related to iron status. Methods: The patients were 1774 treated by maintenance hemo...